Search results for: juvenile idiopathic arthritis

Parents Give Back after Watching Daughter’s Struggle with Systemic Juvenile Idiopathic Arthritis

Staff | February 1, 2014

Diagnosis prompts Steve and Debbie Russell to support the Rheumatology Research Foundation

PR-COIN Initiative Takes Aim at Juvenile Idiopathic Arthritis

Mary Beth Nierengarten | June 1, 2013

The Pediatric Rheumatology Care and Outcomes Improvement Network uses clinical evidence and a network of collaborators to improve outcomes for children with JIA

Molecular Analysis Reveals Potential Treatment Window for Systemic Juvenile Idiopathic Arthritis

Lara C. Pullen, PhD | January 2, 2013

In patients with simultaneous systemic and arthritic components of systemic juvenile idiopathic arthritis (SJIA), these components appear to be related mechanistically. Moreover, the inflammatory pathways of SJIA appear to be distinct from those seen in polyarticular JIA.

Systemic Juvenile Idiopathic Arthritis

Rayfel Schneider, MBBCh, and Ronald M. Laxer, MDCM | May 9, 2012

Changing treatment paradigms in the biologic era

Growing Up Confident with Juvenile Idiopathic Arthritis

Staff | May 9, 2012

While juvenile arthritis can cause joint damage and limit function, rheumatologists strongly encourage children with JIA to live normal lives.

Patient Fact Sheet: Juvenile Idiopathic Arthritis

Staff | May 9, 2012

Several types of arthritis fall under the JIA heading. This inflammation begins before patients reach the age of 16 years, and may involve one or many joints and cause other symptoms such as fevers, rash, and eye inflammation.

Juvenile Idiopathic Arthritis

Staff | January 1, 2009

Patient Fact Sheet

ACR, Arthritis Foundation Host Congressional Briefing to Champion Rheumatology Research

From the College | May 17, 2025

The May 6 event brought together patients, physicians and advocates to challenge misconceptions and advocate for sustained investment in rheumatology research.

FDA Approves New Biosimilar for Adult & Pediatric Arthritis

Michele B. Kaufman, PharmD, BCGP | November 6, 2023

This year, tocilizumab biosimilars have been approved to treat adult and pediatric patients with rheumatic disease, including rheumatoid arthritis, juvenile idiopathic arthritis and more, in both Europe and the U.S.

Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022

Walter P. Maksymowych, MB ChB, FACP, FRCP(C) | December 1, 2022

PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…